WO2013095681A1 - Methods and compositions for the treatment of diverticulosis - Google Patents

Methods and compositions for the treatment of diverticulosis Download PDF

Info

Publication number
WO2013095681A1
WO2013095681A1 PCT/US2012/000576 US2012000576W WO2013095681A1 WO 2013095681 A1 WO2013095681 A1 WO 2013095681A1 US 2012000576 W US2012000576 W US 2012000576W WO 2013095681 A1 WO2013095681 A1 WO 2013095681A1
Authority
WO
WIPO (PCT)
Prior art keywords
glutamine
diverticulosis
compositions
salt
fiber
Prior art date
Application number
PCT/US2012/000576
Other languages
French (fr)
Inventor
Yutaka Niihara
Original Assignee
Emmaus Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020187009799A priority Critical patent/KR20180039187A/en
Priority to EP12860587.0A priority patent/EP2793875B1/en
Application filed by Emmaus Medical, Inc. filed Critical Emmaus Medical, Inc.
Priority to MX2014007382A priority patent/MX351688B/en
Priority to KR1020177020002A priority patent/KR20170087531A/en
Priority to DK12860587.0T priority patent/DK2793875T3/en
Priority to RU2014123433A priority patent/RU2662917C2/en
Priority to AU2012355956A priority patent/AU2012355956B2/en
Priority to CN201280062802.4A priority patent/CN104114165B/en
Priority to JP2014547181A priority patent/JP6060176B2/en
Priority to KR1020177008405A priority patent/KR101848722B1/en
Priority to ES12860587T priority patent/ES2770585T3/en
Priority to BR112014014765A priority patent/BR112014014765A8/en
Priority to EP19199336.9A priority patent/EP3603631B1/en
Priority to KR1020147016785A priority patent/KR20140103281A/en
Publication of WO2013095681A1 publication Critical patent/WO2013095681A1/en
Priority to IN1255/KOLNP/2014A priority patent/IN2014KN01255A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/24—Cellulose or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
  • Diverticulosis refers to a condition where pouches (i.e., diverticula) form along the colon wall.
  • the pouches are typically 5 to 10 millimeters in diameter and are formed in approximately 50 percent of individuals 60 years old or older.
  • diverticulosis Many cases of diverticulosis go undiscovered, because the condition alone does not cause symptoms. Diverticulosis is typically diagnosed after a patient experiences complications, such painful diverticular disease or diverticulitis. In other cases, it is discovered during a screening examination (e.g., colonoscopy).
  • a screening examination e.g., colonoscopy
  • Diverticulosis is usually treated using a combination of nutritional guidelines and medication.
  • a patient may follow a diet regimen involving ingestion of high fiber foods with the objective of consuming 30 to 35 grams of fiber per day.
  • Antispasmodic drugs may be prescribed to relax muscles around the digestive tract. Painkillers may be administered where diverticulitis or other complications of diverticulosis have occurred.
  • FIG. 1 shows L-glutamine (1) and L-glutamine salts and derivatives (2).
  • the present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
  • the present invention provides a method of treating diverticulosis.
  • the method includes ingestion of 0.05 g kg body weight to 10.0 g kg body weight of L- glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
  • the present invention provides acomposition for treating diverticulosis.
  • the composition includes L-glutamine, an L-glutamine salt or an L-glutamine derivative and a fiber supplement.
  • the present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
  • L-glutamine The structure of L-glutamine is shown in FIG. 1, compound 1.
  • L-glutamine salts and derivatives are shown as compound 2 in FIG. 1.
  • Nonlimiting L-glutamine salts and derivatives have the following substituents in reference to compound 2:
  • Ri is NH 2 ;
  • R 2 is NH 2 , NH 3 + , NH 3 Br, NH 3 OPO 3 H, NH 3 OC(0)CH 3 (i.e., acetate salt),
  • NH 3 OC(0)CHCHC0 2 H i.e., fumarate salt - tra olefin
  • NH 3 OC(0)CH(OH)CH(OH)C0 2 H i.e., tartrate salt
  • NH 3 OC(0)CHCHC0 2 H i.e., maleate salt - cis olefin
  • NH 3 OC(O)CH 2 - C(OH)(C0 2 H)CH 2 C0 2 H i.e., citrate salt
  • NH 3 OC(0)C0 2 H i.e., oxalate salt
  • NH 3 OS(0) 2 OH i.e., methanesulfonate salt
  • NH 3 0S(0) 2 C 6 H 4 CH 3 .e.,/?-toluenesulfonate salt
  • R 3 is OH, O " , ONa, OK, OCa, OLi, ONH 2 (CH 2 C 6 H 5 )CH 2 CH 2 NHCH 2 C 6 H 6 (i.e., benzathine salt), ON(CH 2 CH 3 ) 2 CH 2 CH 2 OC(O)C 6 H 3 ClNH 2 (i.e., chloroprocaine salt),
  • ON(CH 3 ) 3 CH 2 CH 2 OH i.e., choline salt
  • ONH 2 (CH 2 CH 2 OH) 2 i.e. , diethanolamine salt
  • ONH 3 CH 2 CH 2 OH i.e., ethanolamine salt
  • ONH 3 CH 2 CH 2 NH 2 i.e., ethyldiamine salt
  • ONH 3 C(CH 2 OH) 3 i.e., tromethamine salt
  • ONH 3 C(CH 3 ) 3 i.e., tertiary-butylamine salt
  • ON(CH 2 CH 3 ) 2 CH 2 CH 2 OC(O)C 6 H 4 NH 2 (i.e., procaine salt)
  • NHCH(CH 3 )CO 2 H
  • NHCH(CH 2 C 8 3 ⁇ 4N)CO 2 H NHCH 2 CO 2 H, NHCH(CH 2 CH 2 C(O)NH 2 )CO 2 H, NHCH(CH 2 C(0)NH 2 )C0 2 H, NHCH(CH(OH)CH 3 )C0 2 H, NHCH(CH 2 OH)C0 2 H,
  • a single compound e.g., L-glutamine
  • a person seeking treatment for diverticulosis e.g., a single compound administered to a person seeking treatment for diverticulosis.
  • a mixture of two or more compounds may be administered.
  • L-glutamine may be aclministered with one or more L- glutamine salts or derivatives.
  • L-glutamine, its salts, derivatives or mixtures may be administered in any suitable way.
  • it is administered as an aqueous solution.
  • the solution may only have L-glutamine, salts or derivatives as dissolved ingredients, or it may include other pharmaceutically acceptable compounds.
  • Nonlimiting examples of such compounds include buffers and flavorants.
  • L-glutamine, its salts, derivatives or mixtures may be administered include: as a suspension in a liquid (e.g., water or juice); as a solid, either as a powder or in another form (e.g. , pill or capsule); as a mixture with food (e.g., yogurt).
  • a liquid e.g., water or juice
  • a solid either as a powder or in another form (e.g. , pill or capsule); as a mixture with food (e.g., yogurt).
  • a mixture with food e.g., yogurt
  • the preceding administration forms may include other pharmaceutically acceptable ingredients.
  • the amount of L-glutamine, salts or derivatives administered according to the present invention typically range from 0.05 g/kg body weight to 10.0 g/kg body weight. Oftentimes, the amount ranges from 0.10 g/kg body weight to 8.0 g/kg body weight. In certain cases, the amount ranges from 0.15 g/kg body weight to 7.0 g/kg body weight.
  • L-glutamine its salts or derivatives are typically administered to a person once per day.
  • the compounds may, however, be aorninistered more than once per day where indicated.
  • compositions of the present invention may be combined with other methods used to treat diverticulosis. For instance, the compositions may be administered as part of a dietary regimen focused on the inclusion of increased fiber.
  • compositions of the present invention may also be administered and/or combined with a fiber supplement such as CITRUCEL, BENEFIBER and METAMUCIL.
  • the fiber supplement may include soluble and/or insoluble fiber, or the supplement may be entirely composed of soluble and/or insoluble fiber.
  • Nonlimiting examples of fiber with which the compositions can be combined include: methylcellulose; wheat dextrin natural soluble fiber; and, psyllium fiber.
  • the fiber may also include combinations of the foregoing types of fibers.
  • Combinations of the compositions and fiber may be of any suitable form.
  • the combination may be, for example, in the form of a powder, a capsule, a caplet, a chewable tablet. It may also be included in other supplement forms, such as drinks or gels.
  • compositions according to the present invention may be used to treat diverticulosis as determined by a number of different methods to image colon pouches.
  • imaging methods include: colonoscopy; computed tomography; and, x-ray based on a barium enema.
  • the number of pouches observed in a patient's colon have been reduced by at least twenty-five (25) percent. In certain cases, the number of pouches have been reduced by at least fifty (50) percent or seventy-five (75) percent. In other cases, the number of pouches have been reduced by at least eighty (80) percent, eighty-five (85) percent, ninety (90) percent, or ninety-five (95) percent.

Abstract

The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutarnine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.

Description

METHODS AND COMPOSITIONS FOR THE
TREATMENT OF DIVERTICULOSIS
This application claims priority benefit of U.S. Provisional Patent Application No.
61/630,831, filed December 19, 2011. The entire content of that application is hereby incorporated by reference herein in its entirety.
Field of the Invention
The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
Background of the Invention
Diverticulosis refers to a condition where pouches (i.e., diverticula) form along the colon wall. The pouches are typically 5 to 10 millimeters in diameter and are formed in approximately 50 percent of individuals 60 years old or older.
The etiology of diverticulosis is not well understood. Current theory focuses on observed nutritional differences between cultures: Those cultures that eat a high fiber diet (e.g., Asia and Africa) have a very low incidence of diverticulosis; those that eat a low fiber diet (e.g., United States and Europe) have a high incidence of diverticulosis. Certain physicians believe that the colon of a person eating a diet low in fiber must exert more pressure than usual to move waste through his colon. The relative high pressure distorts weak spots in the colon where blood vessels pass through the muscle layer of the bowel wall, thereby forming pouches.
Many cases of diverticulosis go undiscovered, because the condition alone does not cause symptoms. Diverticulosis is typically diagnosed after a patient experiences complications, such painful diverticular disease or diverticulitis. In other cases, it is discovered during a screening examination (e.g., colonoscopy).
Diverticulosis is usually treated using a combination of nutritional guidelines and medication. A patient may follow a diet regimen involving ingestion of high fiber foods with the objective of consuming 30 to 35 grams of fiber per day. Antispasmodic drugs may be prescribed to relax muscles around the digestive tract. Painkillers may be administered where diverticulitis or other complications of diverticulosis have occurred.
There is a need in the art for additional compositions and methods that can be used to treat diverticulosis. That is an object of the present invention.
Brief Description of the Figures
FIG. 1 shows L-glutamine (1) and L-glutamine salts and derivatives (2).
Summary of the Invention
The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g kg body weight to 10.0 g kg body weight of L- glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.
In a composition aspect, the present invention provides acomposition for treating diverticulosis. The composition includes L-glutamine, an L-glutamine salt or an L-glutamine derivative and a fiber supplement.
Detailed Description of the Invention The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis.
The structure of L-glutamine is shown in FIG. 1, compound 1. L-glutamine salts and derivatives are shown as compound 2 in FIG. 1. Nonlimiting L-glutamine salts and derivatives have the following substituents in reference to compound 2:
Ri is NH2;
R2 is NH2, NH3 +, NH3Br, NH3OPO3H, NH3OC(0)CH3 (i.e., acetate salt),
NH3OC(0)CHCHC02H (i.e., fumarate salt - tra olefin), NH3OC(0)CH(OH)CH(OH)C02H (i.e., tartrate salt), NH3OC(0)CHCHC02H (i.e., maleate salt - cis olefin), NH3OC(O)CH2- C(OH)(C02H)CH2C02H (i.e., citrate salt), NH3OC(0)C02H (i.e., oxalate salt), NH3OS(0)2OH (i.e., methanesulfonate salt), NH30S(0)2C6H4CH3 ( .e.,/?-toluenesulfonate salt), and,
NH3OC(0)C(0)CH2CH2C02H (i.e., alpha-ketoglutarate salt).
R3 is OH, O", ONa, OK, OCa, OLi, ONH2(CH2C6H5)CH2CH2NHCH2C6H6 (i.e., benzathine salt), ON(CH2CH3)2CH2CH2OC(O)C6H3ClNH2 (i.e., chloroprocaine salt),
ON(CH3)3CH2CH2OH (i.e., choline salt), ONH2(CH2CH2OH)2 (i.e. , diethanolamine salt), ONH3CH2CH2OH (i.e., ethanolamine salt), ONH3CH2CH2NH2 (i.e., ethyldiamine salt),
ONH2(CH3)CH2CH(OH)CH(OH)CH(OH)CH(OH)CH2OH (i.e., meglumine salt),
ONH3C(CH2OH)3 (i.e., tromethamine salt), ONH3C(CH3)3 (i.e., tertiary-butylamine salt), ON(CH2CH3)2CH2CH2OC(O)C6H4NH2 (i.e., procaine salt), NHCH(CH3)CO2H,
NHCH(CH(CH3)2)CO2H, NHCH(CH(CH3)(CH2CH3))CO2H, NHCH(CH2CH(CH3)2)CO2H, NHCH(CH2CH2SCH3)CO2H, NHCH(CH2C6H5)CO2H, NHCH(CH2C6H5OH)CO2H,
NHCH(CH2C8¾N)CO2H, NHCH2CO2H, NHCH(CH2CH2C(O)NH2)CO2H, NHCH(CH2C(0)NH2)C02H, NHCH(CH(OH)CH3)C02H, NHCH(CH2OH)C02H,
NHCH(CH2CH2C02H)C02H, NHCH(CH2C02H)C02H.
Typically, a single compound (e.g., L-glutamine) is administered to a person seeking treatment for diverticulosis. In certain cases, however, a mixture of two or more compounds may be administered. For instance, L-glutamine may be aclministered with one or more L- glutamine salts or derivatives.
L-glutamine, its salts, derivatives or mixtures may be administered in any suitable way. For example, in certain cases it is administered as an aqueous solution. The solution may only have L-glutamine, salts or derivatives as dissolved ingredients, or it may include other pharmaceutically acceptable compounds. Nonlimiting examples of such compounds include buffers and flavorants.
Other, non-limiting examples of ways in which L-glutamine, its salts, derivatives or mixtures may be administered include: as a suspension in a liquid (e.g., water or juice); as a solid, either as a powder or in another form (e.g. , pill or capsule); as a mixture with food (e.g., yogurt). As with the aqueous solution, the preceding administration forms may include other pharmaceutically acceptable ingredients.
The amount of L-glutamine, salts or derivatives administered according to the present invention typically range from 0.05 g/kg body weight to 10.0 g/kg body weight. Oftentimes, the amount ranges from 0.10 g/kg body weight to 8.0 g/kg body weight. In certain cases, the amount ranges from 0.15 g/kg body weight to 7.0 g/kg body weight.
L-glutamine, its salts or derivatives are typically administered to a person once per day. The compounds may, however, be aorninistered more than once per day where indicated. Where compositions of the present invention are used to treat diverticulosis, they may be combined with other methods used to treat diverticulosis. For instance, the compositions may be administered as part of a dietary regimen focused on the inclusion of increased fiber.
Compositions of the present invention may also be administered and/or combined with a fiber supplement such as CITRUCEL, BENEFIBER and METAMUCIL. The fiber supplement may include soluble and/or insoluble fiber, or the supplement may be entirely composed of soluble and/or insoluble fiber. Nonlimiting examples of fiber with which the compositions can be combined include: methylcellulose; wheat dextrin natural soluble fiber; and, psyllium fiber. The fiber may also include combinations of the foregoing types of fibers.
Combinations of the compositions and fiber may be of any suitable form. The combination may be, for example, in the form of a powder, a capsule, a caplet, a chewable tablet. It may also be included in other supplement forms, such as drinks or gels.
Compositions according to the present invention may be used to treat diverticulosis as determined by a number of different methods to image colon pouches. Nonlimiting examples of imaging methods include: colonoscopy; computed tomography; and, x-ray based on a barium enema.
After administration of L-glutamine, its salts or derivatives for three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months or twelve months, the number of pouches observed in a patient's colon have been reduced by at least twenty-five (25) percent. In certain cases, the number of pouches have been reduced by at least fifty (50) percent or seventy-five (75) percent. In other cases, the number of pouches have been reduced by at least eighty (80) percent, eighty-five (85) percent, ninety (90) percent, or ninety-five (95) percent. Experimental Results
A person had a number of diverticula as observed by colonoscopy. The person ingested 30 g of L-glutamine per day as an aqueous solution. After twelve months of L-glutamine administration, the number of diverticula had been reduced by ninety (90) percent.

Claims

CLAIMS:
1. A method of treating diverticulosis, wherein the method comprises ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L- glutamine derivative per day by a person who has diverticulosis.
2. The method according to claim 1, wherein the compound ingested is L-glutamine.
3. The method according to claim 2, wherein the L-glutamine is ingested as part of an aqueous solution or suspension.
4. The method according to claim 3, wherein the L-glutamine is ingested for a period of at least six months.
5. The method according to claim 4, wherein the number of diverticula in the person with diverticulosis is reduced by at least fifty percent.
6. A composition for treating diverticulosis, wherein the composition comprises L- glutamine, an L-glutamine salt or an L-glutamine derivative and a fiber supplement.
7. The composition according to claim 6, wherein the composition comprises L- glutamine.
8. The composition according to claim 7, wherein the fiber is selected from a group of fibers consisting of methylcellulose, wheat dextrin and psyllium.
9. The composition according to claim 8, wherein the composition further comprises a flavorant.
10. The composition according to claim 9, wherein it is in the form of a powder, a capsule, a caplet or a chewable tablet.
PCT/US2012/000576 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis WO2013095681A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
JP2014547181A JP6060176B2 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
CN201280062802.4A CN104114165B (en) 2011-12-19 2012-12-14 For treating the method and composition of diverticulosis
MX2014007382A MX351688B (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis.
EP12860587.0A EP2793875B1 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
DK12860587.0T DK2793875T3 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
RU2014123433A RU2662917C2 (en) 2011-12-19 2012-12-14 Methods and compositions for treatment of diverticulosis
KR1020177008405A KR101848722B1 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
KR1020187009799A KR20180039187A (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
KR1020177020002A KR20170087531A (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
AU2012355956A AU2012355956B2 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
ES12860587T ES2770585T3 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
BR112014014765A BR112014014765A8 (en) 2011-12-19 2012-12-14 methods and compositions for treating diverticulosis
EP19199336.9A EP3603631B1 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
KR1020147016785A KR20140103281A (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis
IN1255/KOLNP/2014A IN2014KN01255A (en) 2011-12-19 2014-06-10 Methods and compositions for the treatment of diverticulosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161630831P 2011-12-19 2011-12-19
US61/630,831 2011-12-19

Publications (1)

Publication Number Publication Date
WO2013095681A1 true WO2013095681A1 (en) 2013-06-27

Family

ID=48669319

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/000576 WO2013095681A1 (en) 2011-12-19 2012-12-14 Methods and compositions for the treatment of diverticulosis

Country Status (13)

Country Link
US (4) US9616041B2 (en)
EP (2) EP3603631B1 (en)
JP (1) JP6060176B2 (en)
KR (4) KR101848722B1 (en)
CN (1) CN104114165B (en)
AU (1) AU2012355956B2 (en)
BR (1) BR112014014765A8 (en)
DK (1) DK2793875T3 (en)
ES (1) ES2770585T3 (en)
IN (1) IN2014KN01255A (en)
MX (1) MX351688B (en)
RU (2) RU2662917C2 (en)
WO (1) WO2013095681A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790545A4 (en) * 2019-07-17 2021-07-28 Emmaus Medical, Inc. Methods and compositions for the treatment of sickle cell diseases and thalassemia

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20200106A7 (en) 2018-06-20 2021-08-06 Axcella Health Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES AND THALASEMIAS
US20230053227A1 (en) * 2021-07-27 2023-02-16 G&S Laboratories, Inc. Dietary fiber compositions

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20040096479A1 (en) 2001-08-24 2004-05-20 Levine Scott David Ultra-high fiber supplement and method of cancer reduction
US20050058671A1 (en) 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
US20070116837A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With Dietary Fiber and Compositions Sweetened Therewith
US20080003265A1 (en) * 2006-06-28 2008-01-03 John Francis Casey Protein and fiber containing dietary supplement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018608A1 (en) * 1994-01-11 1995-07-13 N.V. Nutricia Method of treating disorders of the animal or human body by administering amino acids
JP2000060487A (en) * 1998-08-27 2000-02-29 Kao Corp Constipation improver
US7988989B2 (en) * 2003-05-09 2011-08-02 Freedom Health, Llc Nutritional product for enhancing growth and/or strengthening the immune system of equine foals
CA2938564C (en) * 2006-11-07 2017-04-11 The Procter & Gamble Company Fiber containing compositions and methods of making and using same
RU2454730C1 (en) * 2011-03-15 2012-06-27 Александр Михайлович Пузиков Method of treating diverticulosis in experiment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096479A1 (en) 2001-08-24 2004-05-20 Levine Scott David Ultra-high fiber supplement and method of cancer reduction
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US20050058671A1 (en) 2003-05-09 2005-03-17 Bedding Peter M.J. Dietary supplement and method for treating digestive system-related disorders
US20070116837A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With Dietary Fiber and Compositions Sweetened Therewith
US20080003265A1 (en) * 2006-06-28 2008-01-03 John Francis Casey Protein and fiber containing dietary supplement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2793875A4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3790545A4 (en) * 2019-07-17 2021-07-28 Emmaus Medical, Inc. Methods and compositions for the treatment of sickle cell diseases and thalassemia

Also Published As

Publication number Publication date
EP2793875A4 (en) 2015-06-03
CN104114165A (en) 2014-10-22
ES2770585T3 (en) 2020-07-02
DK2793875T3 (en) 2020-02-24
RU2018126834A (en) 2019-03-14
US10258586B2 (en) 2019-04-16
RU2018126834A3 (en) 2019-04-25
KR20140103281A (en) 2014-08-26
US20190201361A1 (en) 2019-07-04
US20170157080A1 (en) 2017-06-08
RU2662917C2 (en) 2018-07-31
KR20170087531A (en) 2017-07-28
EP3603631C0 (en) 2023-11-29
EP3603631A1 (en) 2020-02-05
BR112014014765A8 (en) 2017-07-04
EP2793875A1 (en) 2014-10-29
AU2012355956B2 (en) 2016-07-21
KR20180039187A (en) 2018-04-17
AU2012355956A1 (en) 2014-07-03
US11304918B2 (en) 2022-04-19
US20220202758A1 (en) 2022-06-30
MX2014007382A (en) 2014-09-22
US9616041B2 (en) 2017-04-11
JP2015500340A (en) 2015-01-05
KR101848722B1 (en) 2018-04-13
US20130178531A1 (en) 2013-07-11
IN2014KN01255A (en) 2015-10-16
KR20170038111A (en) 2017-04-05
BR112014014765A2 (en) 2017-06-13
CN104114165B (en) 2016-10-19
MX351688B (en) 2017-10-25
EP3603631B1 (en) 2023-11-29
JP6060176B2 (en) 2017-01-11
RU2733396C2 (en) 2020-10-01
EP2793875B1 (en) 2020-02-05
RU2014123433A (en) 2016-02-10

Similar Documents

Publication Publication Date Title
US20220202758A1 (en) Methods and compositions for the treatment of diverticulosis
McQuade et al. Anti-colorectal cancer chemotherapy-induced diarrhoea: current treatments and side-effects
CN106687107B (en) Anti-methanogenic compositions and uses thereof
CN111050764A (en) β -hydroxybutyrate and butanediol S enantiomers and methods of use thereof
US20120009278A1 (en) Composition To Retard the Onset of Symptoms of Alzheimer's Disease
JPWO2006098524A1 (en) Preventive and therapeutic agent for stress-induced bowel disease
JP5391685B2 (en) Stomach-adaptive relaxation improver
JP2024508514A (en) Method of treatment with selective CB2 receptor agonists
JP6112767B2 (en) Composition for lowering uric acid level in blood
JP2009196972A (en) Medicinal composition
EP2537528B1 (en) Pharmaceutical compositions containing beta- and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease
US20200246414A1 (en) Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system
Blandizzi et al. Gastrointestinal drugs
Hajiarabi et al. Red Sugar versus Polyethylene Glycol 3350 in Pediatric Functional Constipation: A randomized and Active-Controlled Trial
WO2021193856A1 (en) Renal function protectant
JP2021172639A (en) Pharmaceutical composition
JP2007320949A (en) Agent for suppressing rise in blood sugar level
JP2009173605A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12860587

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014547181

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/007382

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147016785

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012355956

Country of ref document: AU

Date of ref document: 20121214

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014123433

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014014765

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014014765

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140616